<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724369</url>
  </required_header>
  <id_info>
    <org_study_id>IRP101-301</org_study_id>
    <nct_id>NCT04724369</nct_id>
  </id_info>
  <brief_title>Open-Label Study of 18F-mFBG for Imaging Neuroblastoma</brief_title>
  <official_title>A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Approaches to Neuroblastoma Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an&#xD;
      imaging agent for confirming or excluding the presence of neuroblastoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, Phase 3, multi-center, open-label study designed to assess the use of&#xD;
      18F-mFBG PET imaging in subjects with known or presumed neuroblastoma. Eligible participants&#xD;
      will have either histopathologically established diagnosis of neuroblastoma or a presumed&#xD;
      diagnosis based on signs, symptoms, physical examination, imaging findings, and laboratory&#xD;
      and genetic test results.&#xD;
&#xD;
      Subjects will only be administered 18F-mFBG if they have undergone or are scheduled to&#xD;
      undergo a 123I-mIBG or 18F-FDG scan within 30 days of the date of the 18F-mFBG scan. Subjects&#xD;
      should not have received any chemotherapy, immunotherapy or radiotherapy between the clinical&#xD;
      and 18F-mFBG imaging studies.&#xD;
&#xD;
      18F-mFBG PET studies and clinical 123I-mIBG scans will be evaluated off-site by 3 independent&#xD;
      radiologists and/or nuclear medicine physicians who are blinded to all subject information.&#xD;
      Blinded readers will record whether findings on 18F-mFBG and 123I-mIBG scans are consistent&#xD;
      with presence of neuroblastoma (Disease +) or absence of disease (Disease -).&#xD;
&#xD;
      Subject-level diagnostic performance will be assessed on the basis of positive and negative&#xD;
      percent agreement (PPA and NPA) between the blinded 18F-mFBG scan interpretations and disease&#xD;
      status (+ or - for neuroblastoma) as independently assessed by an Expert Panel of pediatric&#xD;
      oncologists.&#xD;
&#xD;
      Secondary efficacy analyses will compare PPA and NPA between 18F-mFBG and 123I-mIBG&#xD;
      interpretations provided by the blinded readers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Comparison of PET imaging interpretation and expert assessment for presence or absence of neuroblastoma tumor</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET Scan Identification of Neuroblastoma</measure>
    <time_frame>Imaging at 60 minutes</time_frame>
    <description>Focal 18F-mFBG uptake (presence or absence) when imaging at 60 minutes with PET/CT or PET/MR, reported as positive and negative predictive agreement with expert oncologist assessment for presence of neuroblastoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of 18F-mFBG PET With Clinical 123I-mIBG Imaging</measure>
    <time_frame>Scan interpretation up to one month after intervention.</time_frame>
    <description>This objective will be assessed using the secondary endpoint of focal increased 123I-mIBG uptake (presence or absence), reported as positive and negative predictive agreement with expert oncologist assessment for presence of neuroblastoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.</measure>
    <time_frame>24 hours following 18F-mFBG administration.</time_frame>
    <description>Description: Assessments based on changes between pre- and post-18F-mFBG administration physical examination findings, vital signs measurements, blood test results including hematology and biochemistry, and electrocardiograms (ECGs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Study Cohort: Subjects with known or presumed neuroblastoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 18F-mFBG Positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for identification of neuroblastoma.&#xD;
Other Names:&#xD;
meta-fluorobenzylguanidine&#xD;
IRP101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-MFBG</intervention_name>
    <description>Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent</description>
    <arm_group_label>Study Cohort: Subjects with known or presumed neuroblastoma</arm_group_label>
    <other_name>meta-fluorobenzylguanidine</other_name>
    <other_name>IRP101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. a) An established diagnosis of neuroblastoma based on unequivocal histopathology from&#xD;
             tissue obtained at any time prior to enrolment in the trial; OR b) A presumed&#xD;
             diagnosis of neuroblastoma based on signs, symptoms, physical examination, imaging&#xD;
             findings, and laboratory and genetic test results, including individuals in whom&#xD;
             therapy has already been empirically initiated.&#xD;
&#xD;
          2. The subject has undergone or is scheduled to undergo evaluation of neuroblastoma&#xD;
             disease status, including at least one functional imaging study (123I-mIBG or&#xD;
             18F-FDG), within 30 days prior to the date of 18F-mFBG imaging, with no interval&#xD;
             therapy between such evaluation and investigational drug administration.&#xD;
&#xD;
          3. Ability of subject or subject's legal guardian to understand and sign a written&#xD;
             informed consent document, including, for subjects age 7-17, an assent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject was previously entered into this study.&#xD;
&#xD;
          2. The subject is pregnant, breast feeding, or menarchal and unwilling to use effective&#xD;
             contraception during the study.&#xD;
&#xD;
          3. The subject has a history or suspicion of significant allergic reaction or anaphylaxis&#xD;
             to any components of the 18F-mFBG imaging agent.&#xD;
&#xD;
          4. The subject is unable to lie flat or remain still for approximately 30 minutes to&#xD;
             allow performance of a PET scan.&#xD;
&#xD;
          5. The subject uses medications that are known to interfere with uptake of NET-dependent&#xD;
             agents and these medications cannot be safely withheld 24 hours before study&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>A F Jacobson, MD, PhD</last_name>
    <phone>401-375-2686</phone>
    <email>jacobson@illuminarp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeta Pandit-Taskar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Weiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yael P Moss√©, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-mFBG</keyword>
  <keyword>meta-fluorobenzylguanidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

